BRUGNOLI, Alberto
BRUGNOLI, Alberto
Dipartimento di Scienze biomediche e chirurgico specialistiche (attivo dal 01/10/2012 al 31/12/2022)
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice
2017 Longo, Francesco; Mercatelli, Daniela; Novello, Salvatore; Arcuri, Ludovico; Brugnoli, Alberto; Vincenzi, Fabrizio; Russo, Isabella; Berti, Giulia; Mabrouk, Omar Sharif; Kennedy, Robert T; Shimshek, Derya R; Varani, Katia; Bubacco, Luigi; Greggio, Elisa; Morari, Michele
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models
2020 Kamakolanu, U. G.; Meyer, M. E.; Yasuda, D.; Polgar, W. E.; Marti, M.; Mercatelli, D.; Pisano, C. A.; Brugnoli, A.; Morari, M.; Zaveri, N. T.
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity
2015 Paolone, Giovanna; Brugnoli, Alberto; Arcuri, Ludovico; Mercatelli, Daniela; Morari, Michele
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia
file con accesso da definire2016 Brugnoli, Alberto; Napolitano, Francesco; Usiello, Alessandro; Morari, Michele
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
2022 Novello, S.; Mercatelli, D.; Albanese, F.; Domenicale, C.; Brugnoli, A.; D'Aversa, E.; Vantaggiato, S.; Dovero, S.; Murtaj, V.; Presotto, L.; Borgatti, M.; Shimshek, D. R.; Bezard, E.; Moresco, R. M.; Belloli, S.; Morari, M.
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives
file con accesso da definire2019 Morari, M.; Mercatelli, D.; Brugnoli, A.; Celeghini, C.; Pisanò, Ca
Novel therapeutic targets in levodopa-induced dyskinesia: in vivo studies in rodent models of Parkinson’s disease
2017 Brugnoli, Alberto
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain.
file con accesso da definire2017 Rimessi, Alessandro; Pavan, C; Ioannidi, E; Nigro, F; Morganti, Claudia; Brugnoli, Alberto; Longo, Francesco; Gardin, C; Ferroni, Letizia; Morari, Michele; Vindigni, V; Zavan, B; Pinton, Paolo
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia
2023 Pisano, C. A.; Mercatelli, D.; Mazzocchi, M.; Brugnoli, A.; Morella, I.; Fasano, S.; Zaveri, N. T.; Brambilla, R.; O'Keeffe, G. W.; Neubig, R. R.; Morari, M.
Role of LRRK2 in the regulation of dopamine receptor trafficking
2017 Rassu, Mauro; Del Giudice, Maria Grazia; Sanna, Simona; Taymans, Jean Marc; Morari, Michele; Brugnoli, Alberto; Frassineti, Martina; Masala, Alessandra; Esposito, Sonia; Galioto, Manuela; Valle, Cristiana; Carri, Maria Teresa; Biosa, Alice; Greggio, Elisa; Crosio, Claudia; Iaccarino, Ciro
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia
2018 Morari, Michele; Brugnoli, Alberto; Pisanò, Clarissa Anna; Novello, Salvatore; Caccia, Carla; Melloni, Elsa; Padoani, Gloria; Vailati, Silvia; Sardina, Marco
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease
2020 Pisano, C. A.; Brugnoli, A.; Novello, S.; Caccia, C.; Keywood, C.; Melloni, E.; Vailati, S.; Padoani, G.; Morari, M.
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia
2018 Gardoni, F; Morari, M; Kulisevsky, J; Brugnoli, Alberto; Novello, S; Pisanò, CLARISSA ANNA; Caccia, C; Mellone, M; Melloni, E; Padoani, G; Sosti, V; Vailati, S; Keywood, C
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats
2020 Brugnoli, A.; Pisano, C. A.; Morari, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice | 2017 | Longo, Francesco; Mercatelli, Daniela; Novello, Salvatore; Arcuri, Ludovico; Brugnoli, Alberto; V...incenzi, Fabrizio; Russo, Isabella; Berti, Giulia; Mabrouk, Omar Sharif; Kennedy, Robert T; Shimshek, Derya R; Varani, Katia; Bubacco, Luigi; Greggio, Elisa; Morari, Michele | |
| Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models | 2020 | Kamakolanu, U. G.; Meyer, M. E.; Yasuda, D.; Polgar, W. E.; Marti, M.; Mercatelli, D.; Pisano, C.... A.; Brugnoli, A.; Morari, M.; Zaveri, N. T. | |
| Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity | 2015 | Paolone, Giovanna; Brugnoli, Alberto; Arcuri, Ludovico; Mercatelli, Daniela; Morari, Michele | |
| Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia | 2016 | Brugnoli, Alberto; Napolitano, Francesco; Usiello, Alessandro; Morari, Michele | file con accesso da definire |
| In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity | 2022 | Novello, S.; Mercatelli, D.; Albanese, F.; Domenicale, C.; Brugnoli, A.; D'Aversa, E.; Vantaggiat...o, S.; Dovero, S.; Murtaj, V.; Presotto, L.; Borgatti, M.; Shimshek, D. R.; Bezard, E.; Moresco, R. M.; Belloli, S.; Morari, M. | |
| Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives | 2019 | Morari, M.; Mercatelli, D.; Brugnoli, A.; Celeghini, C.; Pisanò, Ca | file con accesso da definire |
| Novel therapeutic targets in levodopa-induced dyskinesia: in vivo studies in rodent models of Parkinson’s disease | 2017 | Brugnoli, Alberto | |
| Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. | 2017 | Rimessi, Alessandro; Pavan, C; Ioannidi, E; Nigro, F; Morganti, Claudia; Brugnoli, Alberto; Longo..., Francesco; Gardin, C; Ferroni, Letizia; Morari, Michele; Vindigni, V; Zavan, B; Pinton, Paolo | file con accesso da definire |
| Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia | 2023 | Pisano, C. A.; Mercatelli, D.; Mazzocchi, M.; Brugnoli, A.; Morella, I.; Fasano, S.; Zaveri, N. T....; Brambilla, R.; O'Keeffe, G. W.; Neubig, R. R.; Morari, M. | |
| Role of LRRK2 in the regulation of dopamine receptor trafficking | 2017 | Rassu, Mauro; Del Giudice, Maria Grazia; Sanna, Simona; Taymans, Jean Marc; Morari, Michele; Brug...noli, Alberto; Frassineti, Martina; Masala, Alessandra; Esposito, Sonia; Galioto, Manuela; Valle, Cristiana; Carri, Maria Teresa; Biosa, Alice; Greggio, Elisa; Crosio, Claudia; Iaccarino, Ciro | |
| Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia | 2018 | Morari, Michele; Brugnoli, Alberto; Pisanò, Clarissa Anna; Novello, Salvatore; Caccia, Carla; Mel...loni, Elsa; Padoani, Gloria; Vailati, Silvia; Sardina, Marco | |
| Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease | 2020 | Pisano, C. A.; Brugnoli, A.; Novello, S.; Caccia, C.; Keywood, C.; Melloni, E.; Vailati, S.; Pado...ani, G.; Morari, M. | |
| Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia | 2018 | Gardoni, F; Morari, M; Kulisevsky, J; Brugnoli, Alberto; Novello, S; Pisanò, CLARISSA ANNA; Cacci...a, C; Mellone, M; Melloni, E; Padoani, G; Sosti, V; Vailati, S; Keywood, C | |
| Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats | 2020 | Brugnoli, A.; Pisano, C. A.; Morari, M. |